Articles
January 23, 2023 – Woman’s Doctor: Study Says Women Have Higher Risk of Stomach Cancers
BALTIMORE —In this Woman’s Doctor segment, we take a closer look at stomach cancer. It’s a disease increasing among Americans under 50, particularly women. That’s according to a study by the National Cancer Institute which tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center Dr. Vadim Gushchin said the incidence…
Read MoreJanuary 17, 2023 – Study: Stomach Cancer Increases Among Younger Americans
The rate of stomach cancer is increasing among Americans under 50, particularly women, according to a study by the National Cancer Institute. Researchers tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center surgical oncologist Dr. Vadim Gushchin said the incidence of gastric cancer is very low in the U.S. and…
Read MoreJanuary 11, 2023 – ASCO Guidelines Shine Light on Treatments for Gastroesophageal Cancer
The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer following a systemic review of 18 randomized controlled trials by an expert panel. Read more>
Read MoreJanuary 2, 2023 – Zolbetuximab and Chemotherapy Combination Demonstrates Positive Results for Some Patients with Gastric Cancers, According to Results from Phase 3 Trial
Zolbetuximab in combination with a chemotherapy regimen including capecitabine and oxaliplatin (CAPOX) demonstrated positive results in patients with HER2-negative locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers, according to results of GLOW, a phase 3 clinical trial. Read more>
Read MoreDecember 22, 2022 – Associations Between CDH1 Germline Variants and Hereditary Diffuse Gastric Cancer Syndrome Cancer Phenotypes
In a study reported in The Lancet Oncology, Garcia-Pelaez and colleagues found that presence of germline truncating pathogenic variants or likely pathogenic variants of CDH1 were associated with hereditary diffuse gastric cancer (HDGC) tumor risk syndrome–related cancer phenotypes (lobular breast cancer, diffuse gastric cancer, and gastric cancer), with no apparent association of these phenotypes with CDH1 missense variants of unknown…
Read MoreDecember 20, 2022 – U.S. Minorities Overly Affected By Stomach Cancer: How to Avoid
Stomach (gastric) cancer is not very prevalent in the United States, with only 1.5% of all new cancer diagnoses representing the disease. Despite this, data shows minorities — especially Asian Americans — are more vulnerable to stomach cancer. A new study from Stanford headed by Joo Ha Hwang, MD, Ph.D., professor of gastroenterology and hepatology at Stanford…
Read MoreDecember 19, 2022 – Enhertu Approved in the EU for Patients with Previously Treated HER2-Positive Advanced Gastric Cancer
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi…
Read MoreDecember 9, 2022 – SCIENTIFIC PEER REVIEW OF CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS’ PEER REVIEWED CANCER RESEARCH PROGRAM FOR THE DEPARTMENT OF DEFENSE
Re: Consumer Participation on Scientific Peer Review Panels For Immediate Press Release: SCIENTIFIC PEER REVIEW OF CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS’ PEER REVIEWED CANCER RESEARCH PROGRAM FOR THE DEPARTMENT OF DEFENSE The Congressionally Directed Medical Research Programs’ (CDMRP), Peer Reviewed Cancer Research Program (PRCRP) consumer advocate Amy Jacobs recently participated in the evaluation of research…
Read MoreNovember 29, 2022 – NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer
The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use of nivolumab (Opdivo) plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.1 Read more>
Read MoreNovember 25, 2022 – S’pore firm comes up with world’s first molecular blood test for early detection of gastric cancer
SINGAPORE – When Associate Professor Too Heng-Phon was about to start biotechnology firm Mirxes back in 2010, he asked several of his PhD students to join him, but also warned them that it would be tough going. Two of them decided to help set up the home-grown biotech firm, which went on to develop test…
Read More